New Imaging Procedure for the Localisation of Insulinoma

NCT02127541 · Completed

Last updated 2026-05-28

This clinical trial is testing a new imaging method to locate insulinomas in people with low blood sugar caused by too much insulin.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design single-blind diagnostic study

Participants 52 people

Who can join Ages 18+ · all sexes

Timeline Started 2014-01 · est. completion 2017-11

Where 1 site · Switzerland

What this study is testing ClinicalTrials.gov NCT02127541 ↗

Description as written by the study sponsor.

Insulinoma: Insulinoma are rare, small insulin secreting neuroendocrine tumors. The only curative approach is the surgical excision. The preoperative detection remains a challenge. A non-invasive, highly sensitive tool in localizing the insulinomas would be appreciated in the preoperative work-up of these patients. To this aim Glucagon-like peptide-1 receptor (GLP-1R) imaging (Single Photon Emission Computer Tomography co-registered with a CT; SPECT/CT) could be a convenient tool. The possibly more sensitive approach of targeting GLP-1R using Positron emission tomography (PET/CT) methodology has not been investigated in patients so far.

Treatments tested

Ga -exendin PET/CT, In- exendin SPECT/CT, MRI also known as 68Ga-DOTA-exendin-4, 111In-DOTA-exendin-4, MRI Other

Comparison of different imaging modalities

Main thing measured	Measuring Tumour to Background Ratio
Sponsor	University Hospital, Basel, Switzerland
Conditions studied	Endogenous Hyperinsulinaemic Hypoglycaemia
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02127541 ↗